Literature DB >> 24536028

In reply.

Axel S Merseburger1, Joaquim Bellmunt, Cheryl Jenkins, Chris Parker, John M Fitzpatrick.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24536028      PMCID： PMC3958465          DOI： 10.1634/theoncologist.2013-0395

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  9 in total

1.  Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Horwich; C Parker; T de Reijke; V Kataja
Journal:  Ann Oncol       Date:  2013-06-27       Impact factor: 32.976

Review 2.  Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authors:  Axel S Merseburger; Joaquim Bellmunt; Cheryl Jenkins; Chris Parker; John M Fitzpatrick
Journal:  Oncologist       Date:  2013-05-13

Review 3.  [Pathophysiology and therapy of castration-resistant prostate cancer].

Authors:  A S Merseburger; M A Kuczyk; J M Wolff
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

4.  Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Authors:  Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan; Ronglai Shen; Debashis Ghosh; Ming Zhou; Gary R Macvicar; Soorynarayana Varambally; Jason Harwood; Tarek A Bismar; Robert Kim; Mark A Rubin; Kenneth J Pienta
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

Review 5.  Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.

Authors:  Richard J Lee; Matthew R Smith
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

6.  DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.

Authors:  Martin J Aryee; Wennuan Liu; Julia C Engelmann; Philipp Nuhn; Meltem Gurel; Michael C Haffner; David Esopi; Rafael A Irizarry; Robert H Getzenberg; William G Nelson; Jun Luo; Jianfeng Xu; William B Isaacs; G Steven Bova; Srinivasan Yegnasubramanian
Journal:  Sci Transl Med       Date:  2013-01-23       Impact factor: 17.956

7.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 8.  Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer.

Authors:  John M Fitzpatrick; Ronald de Wit
Journal:  Eur Urol       Date:  2013-07-25       Impact factor: 20.096

9.  Castration-resistant prostate cancer: AUA Guideline.

Authors:  Michael S Cookson; Bruce J Roth; Philipp Dahm; Christine Engstrom; Stephen J Freedland; Maha Hussain; Daniel W Lin; William T Lowrance; Mohammad Hassan Murad; William K Oh; David F Penson; Adam S Kibel
Journal:  J Urol       Date:  2013-05-09       Impact factor: 7.450
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.